Gossamer Bio, Inc.

NASDAQ:GOSS

Biotechnology

Healthcare
$11.43 +3.24%

+$0.01 today

Market cap
$69.91M
Beta
2.04
P/E (TTM)
-0.2
EPS (TTM)
-$0.77
52W Low $0.11High $3.87

Volume 0.24M

Average 19.76M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$171.27M

FY 2025 · Annual

Investing Cash Flow

$156.36M

FY 2025 · Annual

+438.7% YoY

Financing Cash Flow

$6.42M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(234M)(229.38M)(179.82M)(56.53M)(170.37M)
Depreciation & Amortization5.17M4.43M4.39M4.15M1M
Deferred Income Tax00000
Stock-Based Compensation32.01M42.55M28.52M20.62M10.56M
Change in Working Capital774K(4.46M)(14.84M)39.46M(13.63M)
Accounts Receivables000(5.34M)(6.89M)
Inventory00000
Accounts Payables(4.43M)(1.81M)3.99M(1.66M)(2.75M)
Other Working Capital5.2M(2.65M)(18.83M)46.45M(3.99M)
Other Non-Cash Items7.17M(177K)2.6M(11.17M)1.18M
Operating Cash Flow(188.89M)(187.03M)(159.16M)(3.47M)(171.27M)
Capital Expenditures(1.62M)(475K)00(79K)
Acquisitions (Net)0(65K)000
Purchases of Investments(152.03M)(238.06M)(441.67M)(494.78M)(227.11M)
Sales of Investments36.23M237.5M330.7M523.8M383.54M
Other Investing Activities(75K)65K000
Investing Cash Flow(117.43M)(1.04M)(110.97M)29.02M156.36M
Debt Repayment0(5.81M)(11.61M)(12.58M)0
Common Stock Issued0119.95M201.32M464K6.43M
Common Stock Repurchased000629K0
Dividends Paid00000
Other Financing Activities3.33M2.95M444K00
Financing Cash Flow3.33M117.09M190.15M(11.49M)6.43M
Effect of Forex Changes(165K)(517K)110K(102K)141K
Net Change in Cash(303.15M)(71.49M)(79.86M)13.97M(8.34M)
Free Cash Flow(190.51M)(187.51M)(159.16M)(3.47M)(171.35M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$170.4M
+ D&A$1.0M
+ Stock-Based Comp$10.6M
+ Deferred Tax$0
- Working Capital-$13.6M
+ Other Non-Cash$1.2M
= Operating Cash Flow-$171.3M
- Capex-$79.0K
= Free Cash Flow-$171.3M

Analysis

FY2025 free cash flow is -$171.3M. FCF conversion is 100.6% of net income. Operating cash flow was -$171.3M, with capex of -$79.0K. The largest bridge item is Working Capital at -$13.6M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 10, 2026
8-KCurrent reportNov 10, 2026
SC 13G/ASC 13G/A filingNov 6, 2026
SC 13GSC 13G filingNov 6, 2026
SC 13D/ASC 13D/A filingOct 29, 2026

Does GOSS generate free cash flow?

Gossamer Bio, Inc. (GOSS) generated -$171.34M of free cash flow in fiscal 2025.

How much operating cash flow does GOSS produce?

Operating cash flow was -$171.27M, before capital expenditures of $79,000.00.